LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
Status:
Recruiting
Trial end date:
2026-12-30
Target enrollment:
Participant gender:
Summary
This is a open lable, single-center phase Ib/IIa study for patients with local advanced or
metastastic NSCLC or ES-SCLC, who failed with previous anti-PD-1/PD-L1 therapy. The aim is to
observe and evaluate the safety, tolerability and efficacy of LK101 injection combined with
pembrolizumab or durvalumab respectively in the incurable NSCLC and SCLC.
Phase:
Phase 1
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences